Non-standard amino acid conjugates of amphetamine and processes for making and using the same
View Patent ↗Disclosed are amphetamine prodrug compositions comprising at least one non-standard amino acid conjugate of amphetamine, a salt thereof, a derivative thereof, or a combination thereof. Methods of making and using the same are also disclosed.
1. A composition for treating a human or animal patient having attention deficit hyperactivity disorder, comprising at least one conjugate, the conjugate comprising amphetamine and homoarginine; a salt of the conjugate thereof, or a combination thereof.
2. The composition of claim 1 , wherein the composition has a reduced pharmacological activity when administered by parenteral routes.
3. The composition of claim 1 , wherein the salt of the conjugate is a mesylate, a hydrochloride salt, a sulfate, an oxalate, a triflate, a citrate, a malate, a tartrate, a phosphate, a nitrate, a benzoate, or a mixture thereof.
4. The composition of claim 1 , wherein the composition is in the form of a tablet, a capsule, a caplet, a troche, a lozenge, an oral powder, a solution, a oral film, a thin strip, or a suspension.
5. The composition of claim 4 , wherein the tablet, troche, or lozenge is chewable.
6. The composition of claim 1 , wherein the conjugate, the salt of the conjugate, or the combination thereof is present in the amount of from about 1 mg to about 500 mg.
7. The composition of claim 1 , wherein the conjugate, the salt of the conjugate, or the combination thereof is present in the amount of from about 5 mg to about 250 mg.
8. The composition of claim 1 , wherein the conjugate, the salt of the conjugate, or the combination thereof is present in the amount of from about 10 mg to about 100 mg.
9. The composition of claim 1 , wherein the conjugate, the salt of the conjugate, or the combination thereof is in an amount sufficient to provide a therapeutically bioequivalent AUC when compared to amphetamine alone, but does not provide a C max spike.
10. The composition of claim 1 , wherein the conjugate, the salt of the conjugate, or the combination thereof is in an amount sufficient to provide a therapeutically bioequivalent AUC when compared to amphetamine alone, but does not provide an equivalent C max .